Audentes Therapeutics IPO

7/20/2016

IPO

$75,000,000

We currently intend to use the net proceeds from this offering for the following purposes: approximately $18.0 to $20.0 million to advance AT132 for the treatment of XLMTM through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $13.0 to $15.0 million to advance AT342 for the treatment of Crigler-Najjar through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT982 for the treatment of Pompe disease through preliminary results from a Phase 1/2 clinical trial expected in the second half of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT307 for the treatment of CASQ2-CPVT through submission of an IND or CTA in 2017; approximately $7.0 to $10.0 million to operate and expand our internal manufacturing facility; and the remainder for working capital and other general corporate purposes,

Publicly-held

Biopharmaceutical

600 California St. 17th Floor
San Francisco, CA 94108
USA

Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.